FDA Finalizes 12-Digit NDC Rule, Setting March 2033 Deadline for Full System Conversion

A seven-year compliance clock is now running for every manufacturer, repackager, and supply chain partner operating under FDA's final rule revising the National Drug Code format. The rule mandates a uniform 12-digit NDC across all FDA-listed human drugs, biological products, and animal drugs, replacing the current variable 10-digit structure on March 7, 2033.

For labeling and QA teams, the operational sequence is precise. FDA will continue assigning 10-digit NDCs through March 6, 2033. On the effective date, the agency will automatically convert all previously assigned 10-digit NDCs to the 12-digit format by adding leading zeros to the labeler code, product code, and/or package code segments. Registrants will not need to submit new or updated drug listing files solely for the format change; FDA will update listing records centrally.

A three-year labeling transition period runs from March 7, 2033 through March 6, 2036. During that window, FDA does not intend to object to continued use of 10-digit NDCs on labels, provided companies are actively depleting old labeling stock and updating artwork. Drugs bearing a 10-digit NDC after March 7, 2036 may be subject to regulatory action, making early label revision planning a practical risk-management priority rather than a deferred task.

The barcode implications are equally concrete. Under the rule, linear or nonlinear barcode formats are acceptable provided they conform to standards from a widely recognized international standards development organization such as GS1. For products subject to both the NDC barcode label requirement and Drug Supply Chain Security Act (DSCSA) product identifier requirements, a single 2D data matrix barcode encoding the 12-digit NDC via GS1 application identifier 715, along with serial number, lot number, and expiration date, can satisfy both sets of requirements from March 7, 2033 onward. That convergence reduces label real estate demands but requires IT and packaging engineering to validate the combined encoding well ahead of the deadline.

Systems readiness carries equal weight. Manufacturers, distributors, pharmacies, payors, and other supply chain partners must ensure their platforms can process both 10-digit and 12-digit formats concurrently throughout the transition period. The rule explicitly excludes the HIPAA standard 11-digit NDC format used for reimbursement, so dual-format handling will remain a live operational requirement in parallel workflows.

With the effective date fixed and the labeling transition window bounded by a hard enforcement threshold, the measurable outcome for plant heads and regulatory leads is straightforward: label artwork revisions, ERP and serialization system updates, and DSCSA barcode validation must all reach qualified status before March 7, 2033.

Source: FDA via What's New: Drugs RSS Feed, July 8, 2026.